These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade. Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of platelet aggregation by monoclonal antibody reactive with beta 2-microglobulin chain of HLA complex. Curry RA; Messner RP; Johnson GJ Science; 1984 May; 224(4648):509-11. PubMed ID: 6324346 [TBL] [Abstract][Full Text] [Related]
9. Fish oil preparations rich in docosahexaenoic acid modify platelet responsiveness to prostaglandin-endoperoxide/thromboxane A2 receptor agonists. Scheurlen M; Kirchner M; Clemens MR; Jaschonek K Biochem Pharmacol; 1993 Jul; 46(2):245-9. PubMed ID: 8347146 [TBL] [Abstract][Full Text] [Related]
10. Platelet desensitization by arachidonic acid is associated with the suppression of endoperoxide/thromboxane A2 binding to the membrane receptor. Sato T; Hashizume T; Nakao K; Akiba S; Fujii T Biochim Biophys Acta; 1989 Aug; 992(2):168-73. PubMed ID: 2503041 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor. Yu SM; Wu TS; Teng CM Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768 [TBL] [Abstract][Full Text] [Related]
13. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Matthews JS; Jones RL Br J Pharmacol; 1993 Feb; 108(2):363-9. PubMed ID: 8448586 [TBL] [Abstract][Full Text] [Related]
14. Interference of the thromboxane antagonist SK&F 88046 with platelet activation and subsequent desensitization by arachidonic acid and the thromboxane mimetics U46619 and EP171. Vargaftig B; Joseph D; Hatmi M Thromb Res; 1987 May; 46(4):509-17. PubMed ID: 3039684 [TBL] [Abstract][Full Text] [Related]
15. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle. Shaw LA; Batey AJ; Coker SJ Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543 [TBL] [Abstract][Full Text] [Related]
16. A possible role for extracellular bicarbonate in U-46619-induced rat platelet aggregation. Yokoyama K; Kudo I; Nakamura H; Inoue K Thromb Res; 1994 May; 74(4):369-76. PubMed ID: 8085238 [TBL] [Abstract][Full Text] [Related]
17. Further studies on the anti-thromboxane A2 activity of monohydroxylated fatty acids. Lagarde M; Boutillon MM; Guichardant M; Lellouche JP; Beaucourt JP; Vanhove A; Grée R Biochem Pharmacol; 1989 Jun; 38(11):1863-4. PubMed ID: 2735941 [No Abstract] [Full Text] [Related]
18. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo. Ogletree ML; Harris DN; Heran CL; Phillips MB; Michel IM; Goldenberg HJ Eicosanoids; 1988; 1(2):85-91. PubMed ID: 2856188 [TBL] [Abstract][Full Text] [Related]
19. Elevation of platelet cyclic AMP level by thromboxane A2/prostaglandin H2 receptor agonists. Ishikawa Y; Ogawa A Thromb Res; 1991 Dec; 64(6):667-76. PubMed ID: 1665927 [TBL] [Abstract][Full Text] [Related]
20. KRDS, a peptide derived from human lactotransferrin, inhibits thrombin-induced thromboxane synthesis by a cyclooxygenase-independent mechanism. Lévy-Toledano S; Grelac F; Caen JP; Maclouf J Thromb Haemost; 1995 May; 73(5):857-61. PubMed ID: 7482416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]